Krishna Vaddi
Förmögenhet: 17 M $ per 2026-07-31
Förmögenhet: 17 M $ per 2026-07-31
Krishna Vaddi is the founder of Prelude Therapeutics, Inc., founded in 2016, and holds the title of Chief Executive Officer & Director.
Former jobs include Chief Executive Officer at Orsenix LLC from 2014 to 2016, and Executive Director & Group Vice President at Incyte Corp.
from 2010 to 2015.
Education includes a doctorate from the University of Florida and an undergraduate degree from Acharya N.
G.
Ranga Agricultural University.
| Företag | Datum | Antal aktier | Värdering | Värderingsdatum |
|---|---|---|---|---|
| 2026-04-27 | 3 669 054 ( 5,65 % ) | 17 M $ | 2026-07-31 |
| Företag | Position | Start |
|---|---|---|
| PRELUDE THERAPEUTICS INCORPORATED | Grundare | 2016-01-01 |
| Företag | Position | Slut |
|---|---|---|
Orsenix LLC
Orsenix LLC BiotechnologyHealth Technology Operates as a clinical-stage biotech company developing a novel oral form of arsenic trioxide to treat acute promyelocytic leukemia | Verkställande Direktör | 2016-06-01 |
| INCYTE CORPORATION | Direktör/Styrelseledamot | 2015-06-01 |
Aktiva
Inaktiva
Börsnoterade företag
Privata företag
Första gradens relationer
Företag kopplade till första graden
Man
Kvinna
Styrelseledamöter
Chefer
| Privata företag | 5 |
|---|---|
Incyte Corp.
Incyte Corp. Pharmaceuticals: MajorHealth Technology Engages in discovery, development and commercialization of proprietary therapeutics | Health Technology |
University of Florida
University of Florida Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Acharya N. G. Ranga Agricultural University
Acharya N. G. Ranga Agricultural University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Prelude Therapeutics, Inc.
Prelude Therapeutics, Inc. BiotechnologyHealth Technology Discovers and develops medicines targeting chromatin function to treat cancer and rare diseases | Health Technology |
Orsenix LLC
Orsenix LLC BiotechnologyHealth Technology Operates as a clinical-stage biotech company developing a novel oral form of arsenic trioxide to treat acute promyelocytic leukemia | Health Technology |
Välj din utgåva
All finansiell information anpassad till den nationella nivån